5PSQ-050 Neuropsychiatric adverse effects on dolutegravir: experience in a third-level hospital

BACKGROUND: Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is currently among the most commonly used antiretroviral agents. Recent reports have raised concerns about their safety, especially with regard to neuropsychiatric adverse effects (neuropsychiatric AEs)....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Hosp Pharm
Glavni autori: Lopez, TLopez Viñau, de Molina, MD López Malo, de Vicente, M Sáez-Torres, Donoso, J López-Santamaria, Torres, IReyes, Parada, J Hernández
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2018
Teme:
Section 5: Patient safety and quality assurance
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535272/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.404
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items